12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CP-4126: Development discontinued

Clavis and partner Clovis discontinued development of CP-4126 after data from the open-label, international, pivotal Phase II LEAP trial in 367 patients with metastatic pancreatic cancer showed that IV CP-4126 missed the primary endpoint of improving OS in patients with low levels of ENT1 expression vs. gemcitabine. The partners also said there was no difference in OS between treatment arms in the overall population. Median OS was about 6 months in each arm in the overall population (HR=0.99). Adverse events were comparable between treatment arms. CP-4126 was also in a Phase I trial to treat non-small cell lung cancer (NSCLC). Further...

Read the full 483 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >